Drug news
CHMP recommends Komboglyze combination for Type 2 Diabetes
AstraZeneca and Bristol-Myers Squibb Company announced that the Marketing Authorisation Application for Komoboglyze (saxagliptin and metformin HCl immediate-release fixed dose combination) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), as an adjunct to diet and exercise, for the treatment of Type 2 Diabetes in adults who are not adequately controlled on metformin or those already being treated with the combination of saxagliptin and metformin as separate tablets. Komboglyze is already approved in the USA.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.